Warren, Richard B.
McInnes, Iain B.
Nash, Peter
Grouin, Jean-Marie
Lyris, Nikos
Willems, Damon
Taieb, Vanessa
Eells, Jason
Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Funding for this research was provided by:
UCB Pharma
Article History
Received: 5 January 2024
Accepted: 26 February 2024
First Online: 15 March 2024
Declarations
:
: Richard B. Warren: Supported by the Manchester NIHR Biomedical Research Centre; consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis, and UCB Pharma; and honoraria from Astellas, DiCE, GSK, and Union. Iain B. McInnes: Consulting fees and honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Cabaletta, Causeway Therapeutics, Celgene, Evelo, Janssen, Novartis, Lilly, Moonlake, and UCB Pharma; and research support from BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis, and UCB Pharma. Peter Nash: Research grants, clinical trials and honoraria for advice and lectures on behalf of AbbVie, Boehringer Ingelheim, BMS, Eli Lilly, Galapagos/Gilead, GSK, Janssen, Novartis, Pfizer, Samsung, Sanofi, and UCB Pharma. Jean-Marie Grouin: Consulting fees and honoraria from Acticor, Chugai, BeiGene, Inflectis, Inotrem, Ipsen, Janssen, Otsuka, SpikImm, UCB Pharma. Nikos Lyris, Damon Willems, Jason Eells, Vanessa Taieb: Employee and stockholder of UCB Pharma. Philip J. Mease: Research grants from AbbVie, Acelyrin, Amgen, BMS, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma and UCB Pharma; consultancy fees from AbbVie, Acelyrin, Aclaris, Alumis, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, and UCB, and Ventyx Pharma; speakers’ bureau from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma.
: BE OPTIMAL and BE COMPLETE were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Ethical approval was obtained from the relevant institutional review boards at participating sites, and all patients provided written informed consent in accordance with local requirements. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.